| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Another surprising role for exosomes? Improving next-generation sequencing-based cancer diagnostics in liquid biopsies
|
Szallasi, Z.
|
|
|
27 |
4 |
p. 557-558
|
artikel
|
| 2 |
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas
|
Kim, S.J.
|
|
|
27 |
4 |
p. 712-718
|
artikel
|
| 3 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction
|
Klevebro, F.
|
|
|
27 |
4 |
p. 660-667
|
artikel
|
| 4 |
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
|
Ciuleanu, T.
|
|
|
27 |
4 |
p. 680-687
|
artikel
|
| 5 |
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|
Ferrucci, P.F.
|
|
|
27 |
4 |
p. 732-738
|
artikel
|
| 6 |
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
|
Chiorean, E.G.
|
|
|
27 |
4 |
p. 654-660
|
artikel
|
| 7 |
Clinical correlation of extensive-stage small-cell lung cancer genomics
|
Dowlati, A.
|
|
|
27 |
4 |
p. 642-647
|
artikel
|
| 8 |
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials
|
Fizazi, K.
|
|
|
27 |
4 |
p. 699-705
|
artikel
|
| 9 |
Drug–drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists
|
Gelderblom, H.
|
|
|
27 |
4 |
p. 752
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
27 |
4 |
p. ii-iii
|
artikel
|
| 11 |
European cancer mortality predictions for the year 2016 with focus on leukaemias
|
Malvezzi, M.
|
|
|
27 |
4 |
p. 725-731
|
artikel
|
| 12 |
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis
|
Smith, S.G.
|
|
|
27 |
4 |
p. 575-590
|
artikel
|
| 13 |
Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity †
|
Takeda, M.
|
|
|
27 |
4 |
p. 748-750
|
artikel
|
| 14 |
HER2 imaging in the ZEPHIR study
|
Clark, A.S.
|
|
|
27 |
4 |
p. 555-557
|
artikel
|
| 15 |
Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies
|
Petrillo, M.
|
|
|
27 |
4 |
p. 625-634
|
artikel
|
| 16 |
IDH mutations in cancer and progress toward development of targeted therapeutics
|
Dang, L.
|
|
|
27 |
4 |
p. 599-608
|
artikel
|
| 17 |
Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis
|
Truong, J.
|
|
|
27 |
4 |
p. 608-618
|
artikel
|
| 18 |
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
|
Champiat, S.
|
|
|
27 |
4 |
p. 559-574
|
artikel
|
| 19 |
Medication to reduce breast cancer risk: why is uptake low?
|
Butow, P.
|
|
|
27 |
4 |
p. 553-554
|
artikel
|
| 20 |
Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes
|
San Lucas, F.A.
|
|
|
27 |
4 |
p. 635-641
|
artikel
|
| 21 |
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
|
Gebhart, G.
|
|
|
27 |
4 |
p. 619-624
|
artikel
|
| 22 |
Number needed to treat for pricing costly anticancer drugs: the example of regorafenib in metastatic colorectal cancer
|
Graziano, F.
|
|
|
27 |
4 |
p. 747-748
|
artikel
|
| 23 |
Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer
|
Schild, S.E.
|
|
|
27 |
4 |
p. 590-599
|
artikel
|
| 24 |
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas †
|
Ramanathan, R.K.
|
|
|
27 |
4 |
p. 648-653
|
artikel
|
| 25 |
Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial †
|
Fazio, N.
|
|
|
27 |
4 |
p. 668-673
|
artikel
|
| 26 |
Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL) †
|
Cottereau, A.S.
|
|
|
27 |
4 |
p. 719-724
|
artikel
|
| 27 |
Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial
|
Grenader, T.
|
|
|
27 |
4 |
p. 687-692
|
artikel
|
| 28 |
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma †
|
Al-Batran, S.-E.
|
|
|
27 |
4 |
p. 673-679
|
artikel
|
| 29 |
Reply to the letter to the editor ‘Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy’ by Tannock et al.
|
Parker, C.
|
|
|
27 |
4 |
p. 750-751
|
artikel
|
| 30 |
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer †
|
Carter, C.A.
|
|
|
27 |
4 |
p. 693-699
|
artikel
|
| 31 |
Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors
|
van Adrichem, R.C.S.
|
|
|
27 |
4 |
p. 746-747
|
artikel
|
| 32 |
Survival after resection of perihilar cholangiocarcinoma—development and external validation of a prognostic nomogram
|
Groot Koerkamp, B.
|
|
|
27 |
4 |
p. 753
|
artikel
|
| 33 |
Survival in young adults diagnosed with follicular lymphoma
|
Calvo, V.
|
|
|
27 |
4 |
p. 751
|
artikel
|
| 34 |
Table of Contents
|
|
|
|
27 |
4 |
p. iv-vi
|
artikel
|
| 35 |
The GILDA trial finds no survival benefit from intensified screening after primary resection of colorectal cancer: the PulMiCC trial tests the survival benefit of pulmonary metastasectomy for detected asymptomatic lung metastases
|
Treasure, T.
|
|
|
27 |
4 |
p. 745
|
artikel
|
| 36 |
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study
|
Pérez-Valderrama, B.
|
|
|
27 |
4 |
p. 706-711
|
artikel
|
| 37 |
Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations
|
Bousquet, M.
|
|
|
27 |
4 |
p. 738-744
|
artikel
|
Tijdschrift beschrijving